Health

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…

2 days ago
Philips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patientsPhilips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patients

Philips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patients

February 10, 2025 Groundbreaking program that provides technology and training is reducing the impact of stroke, one of the leading…

2 days ago
ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

MELBOURNE, Australia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers…

2 days ago
Pharming Group to participate in February investor conferencePharming Group to participate in February investor conference

Pharming Group to participate in February investor conference

Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in…

2 days ago
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs HoldersGENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the…

2 days ago
Saudi Arabias KFSHRC Continues to Rise as a Globally Renowned Medical CentreSaudi Arabias KFSHRC Continues to Rise as a Globally Renowned Medical Centre

Saudi Arabias KFSHRC Continues to Rise as a Globally Renowned Medical Centre

RIYADH, Saudi Arabia, Feb. 09, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia’s King Faisal Specialist Hospital & Research Centre (KFSHRC) –…

3 days ago
EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis MeetingEYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen…

3 days ago
Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing IntervalsThree-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…

3 days ago
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

February 08, 2025 14:30 ET  | Source: 4D Molecular Therapeutics, Inc. 3E10 vg/eye achieved an 83% reduction in injection burden…

3 days ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 07, 2025 16:30 ET  | Source: ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE…

3 days ago